NEW YORK (GenomeWeb) – UK-based liquid biopsy firm Angle said today that it has inked a comarketing agreement with Qiagen for circulating tumor cell (CTC) technology.

Under the terms of the agreement, the companies will market Angle's Parsortix system for harvesting CTCs alongside Qiagen's liquid biopsy product portfolio, including its next-generation sequencing, PCR, single-cell analysis, and bioinformatics products.

The companies will initially focus on prostate and breast cancer research applications, Angle said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.